Corbus Pharmaceuticals Inc. has divulged new cannabinoid CB1 receptor antagonists or inverse agonists potentially useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases.
Eli Lilly and Co.’s buyout of Ventyx Biosciences Inc. for $1.2 billion at the start of the year brought to the forefront NLR family pyrin domain containing 3 (NLRP3) inhibitors, on which a handful of developers have been working – and research in the space continues to roll out, as with the paper published March 26 in Nature that delved into mechanisms that rev up the NLRP3 inflammasome.
Neurocrine Biosciences Inc. has discovered new peptides acting as corticotropin-releasing factor CRF2 receptor agonists potentially useful for the treatment of obesity.
Everest Medicines Ltd. has agreed to acquire a Singapore-based commercial unit of Hasten Biopharmaceuticals (Asia) Ltd. for $150 million up front, gaining market authorization holder rights to 14 marketed products originally developed by Takeda Pharmaceutical Co. Ltd.
More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.
Abbvie Inc. is buying exclusive rights to develop, manufacture and commercialize two Nav1.8 inhibitors for pain – HSK-55718 and HSK-51155 – from Haisco Pharmaceutical Group Co. Ltd. for $30 million up front and up to $715 million in milestone payments, plus royalties.
There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking 157,159 participants in the UK Biobank over 13 years. This shows that even in the absence of any metabolic disturbance such as elevated lipids, high blood pressure or diabetes, there is an increased risk of heart attack, stroke, peripheral arterial disease, heart failure and liver disease in people with a body mass index over 30.
Chengdu Diao Pharmaceutical Group Co. Ltd. has patented new 1,2,4-triazole compounds characterized as apelin receptor (APLNR) agonists. As such, they are described as useful for the treatment of obesity, hypertension, pulmonary hypertension, heart failure, diabetes, atherosclerosis, osteoporosis and sarcopenia.
The development of glucagon-like peptide 1 receptor (GLP-1R) agonists, such as semaglutide and tirzepatide, has been a game changer in the clinical management of overweight and obesity, but there is interpersonal variability in efficacy of these medications for weight loss, as well as in the incidence of undesired side effects. Investigators from the 23andMe Research Institute have shed some light on how variations in the GLP-1R and GIP receptor (GIPR) genes impact their effectiveness and the occurrence of side effects.
There are new data to chew over in the ongoing controversy about obesity being diagnosed as a disease from a study tracking 157,159 participants in the UK Biobank over 13 years. This shows that even in the absence of any metabolic disturbance such as elevated lipids, high blood pressure or diabetes, there is an increased risk of heart attack, stroke, peripheral arterial disease, heart failure and liver disease in people with a body mass index over 30.
RSS
